Leading the Charge in Alzheimer's Research: Isobel Coleman Appointed CEO of ADDF

A New Era for Alzheimer's Research Under Isobel Coleman

On March 23, 2026, the Alzheimer's Drug Discovery Foundation (ADDF) announced the appointment of Isobel Coleman as its Chief Executive Officer. This pivotal move, heralded as a significant step toward the next generation of Alzheimer's breakthroughs, marks an exciting transition for the organization dedicated to the research and treatment of this debilitating disease.

A Leader with Extensive Experience

Isobel Coleman’s extensive background encompasses leadership roles in public, private, and nonprofit sectors. Notably, she has served as a partner at McKinsey & Company and has held diplomatic positions, including one confirmed by the U.S. Senate with the rank of Ambassador. This diverse experience provides Coleman with unique insights and innovative strategies to lead the ADDF.

During her recent role as the Deputy Administrator of the U.S. Agency for International Development, Coleman oversaw a vast portfolio of over $35 billion and managed a workforce of approximately 15,000 employees. Her successful track record demonstrates her ability to navigate complex organizations and to drive impact in critical missions.

Coleman is stepping into the role at a time when Alzheimer’s research is experiencing unprecedented progress. The ADDF, co-founded by Leonard A. and Ronald S. Lauder in 1998, has been at the forefront of drug discovery, dedicated exclusively to accelerating the development of therapies for Alzheimer's disease through a venture philanthropy model. This innovative approach allows the foundation to fund research in both academia and industry.

Advancing Alzheimer’s Science

The ADDF has made remarkable strides in Alzheimer’s research, including the development of the first Alzheimer's PET scan, Amyvid®, and the blood test, PrecivityAD®. To date, the foundation has provided nearly $400 million to fund 792 programs aimed at drug development, prevention, and biomarkers across 21 countries.

As Coleman takes the reins, she believes the ADDF is uniquely positioned to catalyze further breakthroughs in Alzheimer's science. Her vision aligns with the ADDF’s mission to enhance treatment options through combination therapies and precision medicine. Coleman stated, "I am deeply honored to serve... The ADDF is uniquely positioned to catalyze breakthroughs...to bring positive results to patients and families worldwide."

This sentiment is echoed by Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF, who expressed optimism about the future of the organization under Coleman’s leadership. He mentioned the advances made in diversified clinical trials and the use of artificial intelligence to redefine diagnostics and tracking of Alzheimer's disease, emphasizing a collective goal to shape the future of Alzheimer’s treatment.

A Call to Action

With a commitment to rigorous scientific research and innovation, the ADDF aims to navigate the challenges ahead and transform findings into actionable solutions for patients. Isobel Coleman’s appointment as CEO marks not just a change in leadership but an invigorating infusion of expertise, energy, and vision to drive forward the urgent mission of stopping Alzheimer’s disease.

As the ADDF embarks on this new chapter, they invite supporters and stakeholders to join them in their endeavor to make significant contributions toward curing Alzheimer's. Isobel Coleman’s comprehensive understanding of organizational dynamics, paired with the ADDF's innovative approaches, promises a future filled with hope and potential for individuals and families affected by this devastating illness.

In conclusion, the ADDF stands ready for an inspiring journey towards discovering new avenues for prevention and treatment, honoring the legacy of its founders and the mission to turn the tide against Alzheimer’s disease. For more information about their work and initiatives, interested parties can explore their website at alzdiscovery.org.